Regeneron Pharmaceuticals and its collaborators plan to sequence the exomes all of the UK Biobank participants by then end of 2019.
By the end of 2019, Regeneron plans sequence the exomes of all 500,000 participants in the UK Biobank.
The project, dubbed FinnGen, was announced this week and is slated to run through mid-2023.
With its recently launched BCRquest.com data analysis hub, BC Platforms has teamed with the Accelerated Cure Project for MS and Biogen.
Funded by Biogen, The University of Colorado, and The Global Down Syndrome Foundation, the project will analyze genetics and other biology in 1,000 individuals with the disorder.
Under the arrangement, OMRF will work with Biogen to analyze patient samples and identify biomarkers that indicate responses to particular therapies.
The company has added Biogen, Mount Sinai, and Thermo Fisher Scientific to its client roster and is exploring partnership opportunities with bioinformatics companies.
The firm's platform combines proprietary algorithms and software with its integrated genome-phenome database to uncover relationships between genetic variation and human health outcomes.
Under the Genomic Translation for ALS Clinical Care project, the partners will perform next-generation sequencing and clinical phenotyping on 1,500 ALS patients.
Drug companies are rushing toward genomic databases to inform their searches for new drugs, Reuters reports.
The data generated by 100,000 Genomes Project is being housed on military servers due to attacks by hackers, Naked Security reports.
A new poll finds most US adults are not familiar with personalized medicine, according to HealthDay.
Vox reports that the United Nations' Convention on Biological Diversity decided against a gene drive moratorium.
In Science this week: sequencing of neuroblastomas uncovers alterations linked to prognosis, and more.